Stay updated with breaking news from Nasdaq Cbay. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CymaBay Therapeutics (NASDAQ:CBAY – Free Report) had its price objective hoisted by Raymond James from $33.00 to $34.00 in a report issued on Wednesday morning, Benzinga reports. Raymond James currently has a strong-buy rating on the biopharmaceutical company’s stock. A number of other analysts have also recently commented on the stock. B. Riley lifted their […]
CymaBay Therapeutics (NASDAQ:CBAY – Free Report) had its target price hoisted by Piper Sandler from $19.00 to $33.00 in a research note released on Monday morning, Benzinga reports. Piper Sandler currently has an overweight rating on the biopharmaceutical company’s stock. Several other brokerages have also commented on CBAY. Cantor Fitzgerald reiterated an overweight rating and […]
Arizona State Retirement System reduced its holdings in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) by 16.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 20,496 shares of the biopharmaceutical company’s stock after selling 4,040 shares during the […]
CymaBay Therapeutics (NASDAQ:CBAY – Get Free Report) will release its earnings data after the market closes on Tuesday, November 7th. Analysts expect CymaBay Therapeutics to post earnings of ($0.30) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link. CymaBay Therapeutics (NASDAQ:CBAY – […]
Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) have earned a consensus rating of “Buy” from the twelve ratings firms that are covering the firm, MarketBeat.com reports. Eleven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year target […]